ALFA Filings
Every announcement, straight from the exchange
Every Jeena Sikho Lifecare earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements with these filters
Jeena Sikho is aggressively pivoting from low-margin government business to a high-margin cash-and-carry wellness ecosystem. Management is prioritizing operating leverage and 'prevention-first' health models to drive 30% annual growth.
JSLL reported Q1FY27 revenue of Rs 224.4 Cr (+29% YoY) with an EBITDA margin of 41%. The company is expanding its integrated Ayurveda model across 2,400 operational beds.
Jeena Sikho delivered strong FY26 results with 71% revenue growth and 177% PAT growth, driven by hospital utilization and high-margin product sales. Management targets 4-5x PAT growth over 3-5 years.
Jeena Sikho reported stellar FY26 growth, pivoting from government to high-margin private patients. Management used flamboyant, messianic rhetoric to mask ₹21cr in one-time expenses related to auditor-mandated accounting changes and staff bonuses.
Jeena Sikho reported stellar FY26 performance with Revenue at ₹80,135 Lakhs and PAT at ₹22,218 Lakhs. The company expanded to 2,300 operational beds across 119 centers.
Jeena Sikho reported strong Q4FY26 results with a 55% YoY revenue surge, driven by expanding Ayurveda healthcare services and product reach.